Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P11168
UPID:
GTR2_HUMAN
Alternative names:
Glucose transporter type 2, liver
Alternative UPACC:
P11168; A8K481; B2R936; B7Z547; F8W8V8; Q9UCW9
Background:
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2), also known as Glucose transporter type 2, liver, plays a pivotal role in glucose homeostasis. It facilitates the transport of glucose, fructose, and galactose across cell membranes, contributing to glucose uptake by hepatocytes and beta cells. This protein is also involved in the transcellular transport of glucose in the small intestine and kidney, and can transport dehydroascorbate.
Therapeutic significance:
SLC2A2's dysfunction is linked to Fanconi-Bickel syndrome, a rare disease characterized by hepatorenal glycogen accumulation and impaired glucose utilization. Understanding the role of SLC2A2 could open doors to potential therapeutic strategies for this condition.